Edition:
United States

Health News

Photo

Sangamo in $3 billion gene-editing deal with Gilead Feb 22 2018

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

More Headlines

Social interaction, staff training reduce agitation in dementia patients

(Reuters Health) - An approach to nursing home care that fosters interest and social interaction among patients and staff may reduce agitation and other neuropsychiatric symptoms in dementia sufferers and improve their quality of life, a recent trial suggests.

Feb 22 2018

Soccer is basically medicine, some researchers argue

(Reuters Health) - Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.

Feb 22 2018
Photo

Dutch prosecutors say won't open criminal case against big tobacco firms

AMSTERDAM Dutch prosecutors on Thursday rejected a call by civil groups, hospitals and the city of Amsterdam to open a criminal case against major tobacco companies, saying the firms had adequately warned smokers of the health risks.

Feb 22 2018
Photo

Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.

Feb 22 2018

Health Watch Graphics